July 08, 2013 at 11:30 AM EDT
RDInvesting Provides Investors with Free In-Depth Equity Reports on ACCO, CVM, DANG and SLXP

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

ACCO Brands Corporation (NYSE: ACCO) shares spiked 2.67 percent to close at $6.53 a share Friday. The stock traded between $6.24 and $6.54 on volume of 985,593 shares traded. Analysts at Credit Suisse have recently downgraded the company’s rating to “neutral” from “outperform”. Shares of ACCO Brands have fallen approximately 11.0 percent year-to-date.

Find out more about ACCO Brands including full access to the free equity report at: www.RDInvesting.com/ACCO

CEL-SCI Corporation (NYSEMKT: CVM) shares declined 0.99 percent to close at $0.211 a share Friday. The stock traded in between $0.21 and $0.22 on volume of 234,270 shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” from “neutral”. Shares of CEL-SCI have fallen approximately 22.0 percent year-to-date.

Find out more about CEL-SCI including full access to the free equity report at: www.RDInvesting.com/CVM

E Commerce China Dangdang Inc. (NYSE: DANG) shares increased 0.29 percent to close at $6.99 a share Friday. The stock traded between $6.79 and $7.10 on volume of 1.10 million shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” from “neutral” and currently have a price target of $7.60 on the stock. Shares of Dangdang have gained approximately 68.0 percent year-to-date.

Find out more about Dangdang including full access to the free equity report at: www.RDInvesting.com/DANG

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) shares gained 1.78 percent to close at $67.05 a share Friday. The stock traded in between $65.73 and $67.67 on volume of 528,399 shares traded. Analysts at Bank of America have recently downgraded the company’s rating to “neutral”. Shares of Salix Pharmaceuticals are up approximately 65.0 percent year-to-date.

Find out more about Salix Pharmaceuticals including full access to the free equity report at: www.RDInvesting.com/SLXP

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact: Research Driven Investing info@rdinvesting.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here